Skip to main content

Regeneron Pharmaceuticals(REGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low602.52
Day High613.15
Open:612.06
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDFRefinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDFStockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Premium PDFValueEngine

Latest News

More Stories
Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
Motley Fool - Sat Jun 25, 9:23AM CDT
Motley Fool
Sat Jun 25, 9:23AM CDT
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
PR Newswire - Fri Jun 24, 6:31AM CDT
PR Newswire
Fri Jun 24, 6:31AM CDT
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg...
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Globe Newswire - Fri Jun 24, 6:30AM CDT
Globe Newswire
Fri Jun 24, 6:30AM CDT
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and...

Latest Articles

number cruncher
15 U.S.-listed companies with great revenue and superior earnings growth
Market movers: Stocks that saw action on Tuesday - and why
Regeneron says its COVID-19 antibody drug could be less effective against Omicron variant
number cruncher
15 stocks with surprisingly strong earnings momentum
Market movers: Stocks that saw action on Tuesday - and why
number cruncher
These 10 U.S. large-cap stocks demonstrate consistent, solid profitability
number cruncher
These 15 U.S. stocks with growing profits also score well on ESG risk
Market movers: Stocks that saw action on Monday - and why
Renewable energy, pot stocks top losers as election results leave Wall Street hanging
Eli Lilly pauses trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
Market movers: Stocks that saw action on Thursday - and why
Market movers: Stocks that saw action on Monday - and why

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2022.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2022 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.